Moderna Merck Melanoma Vaccine: Phase 3 Data Explained
The Moderna Merck melanoma vaccine plus Keytruda cut recurrence or death risk by 42% in a Phase 3 trial of 1,137 patients. Not yet approved.
The Moderna Merck melanoma vaccine plus Keytruda cut recurrence or death risk by 42% in a Phase 3 trial of 1,137 patients. Not yet approved.